Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Genitourinary 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 136Unspecified Adult Solid Tumor, Protocol Specific 122Leukemia, Lymphocytic, Chronic, B-Cell 119Lymphoma 103Breast Neoplasms 102Neoplasms 99Lymphoma, Follicular 98Burkitt Lymphoma 98Lymphoma, Large B-Cell, Diffuse 97Lymphoma, Non-Hodgkin 94Leukemia, Myeloid, Acute 89Lymphoma, Mantle-Cell 88Lymphoma, B-Cell, Marginal Zone 81Neoplasm Metastasis 80Lymphoma, Large-Cell, Immunoblastic 73Carcinoma, Non-Small-Cell Lung 68Melanoma 64Hodgkin Disease 64Lymphoma, T-Cell, Cutaneous 63Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 60Lymphoma, Large-Cell, Anaplastic 60Lung Neoplasms 60Prostatic Neoplasms 58Brain Neoplasms 58Astrocytoma 57Mycosis Fungoides 55Colonic Neoplasms 55Glioblastoma 54Sezary Syndrome 52Ovarian Neoplasms 52

Interventions

veliparib 2Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × NIH × Hereditary Breast and Ovarian Cancer Syndrome × Clear all
NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 1 Completed
98 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

NCT00535119 2015-05-22

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

National Cancer Institute (NCI)

Phase 1 Completed
107 enrolled
BreastGynecologic

Hereditary Breast and Ovarian Cancer Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡